Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

Cellular Oncology

Volumn 38, Issue 2, 2015, Pages 119-129

  Gotink, Kristy J ^a   Rovithi, Maria ^a   de Haas, Richard R ^a   Honeywell, Richard J ^a   Dekker, Henk ^a   Poel, Dennis ^a   Azijli, Kaamar ^a   Peters, Godefridus J ^a   Broxterman, Henk J ^a   Verheul, Henk M W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cross resistance; Lysosomes; mTOR inhibitor; Tyrosine kinase inhibitor

Indexed keywords

CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PAZOPANIB; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SORAFENIB; SULFONAMIDE; SUNITINIB;

ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SULFONAMIDES; TANDEM MASS SPECTROMETRY;

EID: 84940002898     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-015-0218-8     Document Type: Article

References (38)

1. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, The protein kinase complement of the human genome. Science 298, 1912–1934 (2002)
2. R.J. Motzer, T.E. Hutson, D. Cella, J. Reeves, R. Hawkins, J. Guo, J.P. Nathan, M. Staehler, P. de Souza, J.R. Merchan, E. Boleti, K. Fife, J. Jin, R. Jones, H. Uemura, U. De Giorgi, U. Harmenberg, J. Wang, C.N. Sternberg, K. Deen, L. McCann, M.D. Hackshaw, R. Crescenzo, L.N. Pandite, T.K. Choueiri, Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369, 722–731 (2013)
3. N. Peled, M.W. Wynes, N. Ikeda, T. Ohira, K. Yoshida, J. Qian, M. Ilouze, R. Brenner, Y. Kato, C. Mascaux, F.R. Hirsch, Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell. Oncol. 36, 277–278 (2013)
4. R. Sabbatini, C. Ortega, G. Procopio, C. Masini, E. Galligioni, C. Porta, Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. Future Oncol. 9, 831–843 (2013)
5. H.M. Westgeest, N.P. van Erp, R.J. Honeywell, R. Hoekstra, G.J. Peters, H.M. Verheul, Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure. J. Clin. Oncol. 31, e83–86 (2013)
6. J. Rautiola, T. Utriainen, K. Peltola, H. Joensuu, P. Bono, Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma. Acta Oncol. 53, 113–118 (2014)
7. J.F. Gainor, A.T. Shaw, Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J. Clin. Oncol. 31, 3987–3996 (2013)
8. K.J. Gotink, H.J. Broxterman, M. Labots, R.R. de Haas, H. Dekker, R.J. Honeywell, M.A. Rudek, L.V. Beerepoot, R.J. Musters, G. Jansen, A.W. Griffioen, Y.G. Assaraf, R. Pili, G.J. Peters, H.M. Verheul, Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin. Cancer Res. 17, 7337–7346 (2011)
9. E.A. Kuczynski, D.J. Sargent, A. Grothey, R.S. Kerbel, Drug rechallenge and treatment beyond progression–implications for drug resistance. Nat. Rev. Clin. Oncol. 10, 571–587 (2013)
10. VU University Medical Center. Phase II study of sunitinib rechallenge in patients with metastatic renal cell carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 May 31]. Available from: http://clinicaltrials.gov/show/NCT02071641 NLM Identifier: NCT02071641
11. K.A. Olaussen, F. Commo, M. Tailler, L. Lacroix, I. Vitale, S.Q. Raza, C. Richon, C.P. Dessen, V. Lazar, J.C. Soria, G. Kroemer, Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene 28, 4249–4260 (2009)
12. E. Martinelli, T. Troiani, F. Morgillo, G. Rodolico, D. Vitagliano, M.P. Morelli, C. Tuccillo, L. Vecchione, A. Capasso, M. Orditura, F. De Vita, S.G. Eckhardt, M. Santoro, L. Berrino, F. Ciardiello, Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin. Cancer Res. 16, 4990–5001 (2010)
13. J.S. Lind, A.M. Dingemans, H.J. Groen, F.B. Thunnissen, O. Bekers, D.A. Heideman, R.J. Honeywell, E. Giovannetti, G.J. Peters, P.E. Postmus, R.J. van Suylen, E.F. Smit, A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16, 3078–3087 (2010)
14. R. Honeywell, K. Yarzadah, E. Giovannetti, N. Losekoot, E.F. Smit, M. Walraven, M.J.S. Lind, C. Tibaldi, H.M. Verheul, G.J. Peters, Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci. 878, 1059–1068 (2010)
15. P. Saftig, B. Schroder, J. Blanz, Lysosomal membrane proteins: life between acid and neutral conditions. Biochem. Soc. Trans. 38, 1420–1423 (2010)
16. L.B. Saltz, L.S. Rosen, J.L. Marshall, R.J. Belt, H.I. Hurwitz, S.G. Eckhardt, E.K. Bergsland, D.G. Haller, A.C. Lockhart, C.M. Rocha Lima, X. Huang, S.E. DePrimo, E. Chow-Maneval, R.C. Chao, H.J. Lenz, Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol. 25, 4793–4799 (2007)
17. Z.A. Knight, H. Lin, K.M. Shokat, Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10, 130–137 (2010)
18. H. Yang, B. Higgins, K. Kolinsky, K. Packman, W.D. Bradley, R.J. Lee, K. Schostack, M.E. Simcox, S. Kopetz, D. Heimbrook, B. Lestini, G. Bollag, F. Su, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. 72, 779–789 (2012)
19. R.B. Corcoran, H. Ebi, A.B.. Turke, E.M. Coffee, M. Nishino, A.P. Cogdill, R.D. Brown, P. Della Pelle, D. Dias-Santagata, K.E. Hung, K.T. Flaherty, A. Pris, J.A. Wargo, J. Settleman, M. Mino-Kenudson, J.A. Engelman, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer. Discov. 2, 227–235 (2012)
20. S. Gusenbauer, P. Vlaicu, A. Ullrich, HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene 32, 3846–3856 (2013)
21. D. Huang, Y. Ding, M. Zhou, B.I. Rini, D. Petillo, C.N. Qian, R. Kahnoski, P.A. Futreal, K.A. Furge, B.T. Teh, Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70, 1063–1071 (2010)
22. H.J. Hammers, H.M. Verheul, B. Salumbides, R. Sharma, M. Rudek, J. Jaspers, P. Shah, L. Ellis, L. Shen, S. Paesante, Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol. Cancer Ther. 9, 1525–1535 (2010)
23. H. Xin, C. Zhang, A. Herrmann, Y. Du, R. Figlin, H. Yu, Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69, 2506–2513 (2009)
24. F. Yang, C. Brown, R. Buettner, M. Hedvat, R. Starr, A. Scuto, A. Schroeder, M. Jensen, R. Jove, Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol. Cancer Ther. 9, 953–962 (2010)
25. T. Anastassiadis, S.W. Deacon, K. Devarajan, H. Ma, J.R. Peterson, Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039–1045 (2011)
26. C. Bender, A. Ullrich, PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines. Int. J. Cancer 131, E45–55 (2012)
27. B.B. Hasinoff, D. Patel, K.A. O’Hara, Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol. Pharmacol. 74, 1722–1728 (2008)
28. J. Menke, J. Kriegsmann, C.C. Schimanski, M.M. Schwartz, A. Schwarting, V.R. Kelley, Autocrine CSF-1 and CSF-1 receptor coexpression promotes renal cell carcinoma growth. Cancer Res. 72, 187–200 (2012)
29. R. Kumar, M.C. Crouthamel, D.H. Rominger, R.R. Gontarek, P.J. Tummino, R.A. Levin, A.G. King, Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 101, 1717–1723 (2009)
30. P.B. Makhov, K. Golovine, A. Kutikov, E. Teper, D.J. Canter, J. Simhan, J.R.G. Uzzo, V.M. Kolenko, Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol. Cancer Ther. 11, 1510–1517 (2012)
31. A.M. Ellegaard, L. Groth-Pedersen, V. Oorschot, J. Klumperman, T. Kirkegaard, J. Nylandsted, M. Jäättelä, Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance. Mol. Cancer Ther. 12, 2018–2030 (2013)
32. M. Szwed, K.D. Kania, Z. Jozwiak, Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin. Cell. Oncol. 37, 421–428 (2014)
33. H.J. Broxterman, K.J. Gotink, H.M. Verheul, Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist. Updat. 12, 114–126 (2009)
34. R. Rudalska, D. Dauch, T. Longerich, K. McJunkin, T. Wuestefeld, T.W. Kang, A. Hohmeyer, M. Pesic, J. Leibold, A. von Thun, P. Schirmacher, J. Zuber, K.H. Weiss, S. Powers, N.P. Malek, M. Eilers, B. Sipos, S.W. Lowe, R. Geffers, S. Laufer, L. Zender, In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat. Med. 20, 1138–46 (2014)
35. M.H. Hung, W.T. Tai, C.W. Shiau, K.F. Chen, Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy. World J. Gastroenterol. 20, 15269–74 (2014)
36. T.E. Hutson, B. Escudier, E. Esteban, G.A. Bjarnason, H.Y. Lim, K.B. Pittman, P. Senico, A. Niethammer, D.R. Lu, S. Hariharan, R.J. Motzer, Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 32, 760–767 (2014)
37. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, S. Bracarda, V. Grünwald, J.A. Thompson, R.A. Figlin, N. Hollaender, G. Urbanowitz, W.J. Berg, A. Kay, D. Lebwohl, A. Ravaud, RECORD-1 study group. efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008)
38. Netherlands Working Group on Immunotherapy of Oncology. Rotating Pazopanib and Everolimus to Avoid Resistance (ROPETAR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 May 31]. Available from: http://clinicaltrials.gov/show/NCT01408004 NLM Identifier: NCT01408004